Multiple Myeloma

Teclistamab monotherapy significantly improved PFS and OS vs standard-of-care therapy in relapsed/refractory multiple myeloma as early as the second line.

The top 5 OncLive TV videos of the week cover insights in lung cancer, bladder cancer, gastrointestinal cancer, and multiple myeloma.

Bone marrow Immune Atlas in myeloma linked immune system/tumor interactions with disease aggressiveness, potentially improving prognosis and risk stratification.

The EMA is reviewing a Type II variation application to expand teclistamab’s label for use with SC daratumumab in relapsed/refractory myeloma.

Here is your Q1 2026 preview spotlighting 5 FDA decisions to watch, including upcoming PDUFAs for tabelecleucel, pembrolizumab, and more.

The top 5 OncLive TV videos of the week cover insights in leukemia, lung cancer, multiple myeloma, indolent systemic mastocytosis, and pancreatic cancer.

Saad Z. Usmani, MD, MBA, FACP, FASCO, is renowned leader whose work has helped redefine treatment standards and extend the lives of patients worldwide.

Real-world elranatamab led to higher response rates despite less favorable baseline characteristics vs real-world teclistamab in R/R multiple myeloma.

The top 5 OncLive TV videos of the week cover insights in myeloma, AML, Ph-positive ALL, pediatric low-grade glioma, and nonadvanced systemic mastocytosis.

The FDA approved T-DXd plus pertuzumab in HER2+ breast cancer, subcutaneous amivantamab in EGFR+ NSCLC, and rucaparib in BRCA-mutated mCRPC.

Tumor burden and disease status were not correlated with CRS risk or severity in newly diagnosed, relapsed/refractory myeloma managed with elranatamab.

Anito-cel showed deepening responses in patients with relapsed or refractory myeloma enrolled in the phase 2 iMMagine-1 study.

The FDA has given a national priority voucher to teclistamab plus daratumumab for relapsed/refractory multiple myeloma, based on MajesTEC-3 data.

The top 5 OncLive TV videos of the week cover insights in acute myeloid leukemia, follicular lymphoma, multiple myeloma, and Ph+ B-ALL.

With longer median follow-up, talquetamab plus pomalidomide produced an ORR of 85.7% in patients with relapsed/refractory multiple myeloma in MonumenTAL-2.

The combination of belantamab mafodotin, pomalidomide, and dexamethasone showed a median PFS of 32.6 months in relapsed/refractory multiple myeloma.

Experts reflect on pivotal data from the 2025 ASH Annual Meeting that are set to change practice in AML, MZL, FL, and multiple myeloma.

The in vivo, BCMA-directed CAR T-cell therapy produced initial MRD-negative responses and persistent CAR T-cell expansion in 4 patients with relapsed/refractory myeloma.

GC012F/AZD0120 produced responses in high-risk, transplant-eligible multiple myeloma, as well as transplant-ineligible, newly diagnosed disease.

Early teclistamab discontinuation after deep response showed PFS comparable to continuous therapy in relapsed/refractory myeloma in the LimiTEC trial.

Teclistamab/daratumumab improved survival outcomes and led to deep MRD-negative responses vs daratumumab-based regimens in relapsed/refractory myeloma.

Triplet therapy with tagraxofusp/azacitidine/venetoclax led to high remission rates and had a safety profile similar to that of tagraxofusp alone in BPDCN.

Talquetamab plus teclistamab produced a high ORR and CR or better rate in relapsed/refracotry multiple myeloma with true extramedullary disease.

Linvoseltamab monotherapy produced responses and was safe in newly diagnosed multiple myeloma.

AZD0120 CAR T therapy shows rapid, deep responses and manageable safety in R/R myeloma, with ultra-fast manufacturing and strong early durability.